Publications
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
Citation
Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, Jairath V. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. BioDrugs. 2020 Dec;34(6):713-721. doi: 10.1007/s40259-020-00451-w. PMID: 33105016.
Abstract
The inflammatory bowel diseases (IBDs) are chronic immune-mediated inflammatory disorders, including ulcerative colitis (UC) and Crohn’s disease (CD). IBD results from a complex interplay between environmental, microbial, and genetic factors to create an abnormal immunological response leading to intestinal inflammation.
